Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

Summary

This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation

Timeline

Start

2016-11

Primary completion

2017-12

Completion

2018-08

Drugs

Indications